Catalytic topoisomerase II inhibitors in cancer therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• DNA topoisomerase II is a critical nuclear enzyme and a primary target for antineoplastic agents.
• Topoisomerase II-directed agents function by interfering with its catalytic cycle.
• Agents are classified as poisons (stabilizing covalent complexes) or catalytic inhibitors (acting on other cycle steps).

Purpose of the Study:

• To review the mechanisms and biological activities of various DNA topoisomerase II catalytic inhibitors.
• To emphasize therapeutically utilized compounds within this class.
• To discuss future applications and development of catalytic topoisomerase II inhibitors.

Main Methods:

• Literature review focusing on DNA topoisomerase II catalytic inhibitors.
• Analysis of mechanisms of action, including DNA binding interference, noncovalent complex stabilization, and ATP binding inhibition.
• Examination of diverse biological activities and therapeutic applications.

Main Results:

• Catalytic inhibitors represent a heterogeneous group with varied mechanisms, including DNA binding interference (e.g., aclarubicin, suramin), noncovalent complex stabilization (e.g., merbarone, ICRF-187), and ATP binding inhibition (e.g., novobiocin).
• Some inhibitors, like fostriecin, may possess additional biological targets.
• Therapeutic applications extend beyond antitumor activity to include cardioprotection (ICRF-187) and potentiation of other agents (suramin, novobiocin).

Conclusions:

• DNA topoisomerase II catalytic inhibitors offer diverse mechanisms and applications, including anticancer, cardioprotective, and modulatory roles.
• Understanding these varied functions is crucial for optimizing their therapeutic use.
• Further research into this class of compounds holds promise for novel therapeutic strategies.